Our study found that BNP levels at 24 h after ECMO treatment decreased significantly compared to before ECMO treatment, and the difference was statistically significant, indicating that VA-ECMO was beneficial for cardiac treatment in patients with CS [9]. The gene discussed is NPPB; the disease is Cowden syndrome 1.